The art of repositioning drugs: An interview with NovaLead Pharma’s Supreet Deshpande

Inventing a new drug requires huge financial commitment and it’s a lengthy process until it reaches patients in need. However, discovering a new application of an already clinically-approved drug saves you both time and allows you to fully utilise the power of your existing arsenal. Since the original drug application has a known function and toxicity, drug repurposing saves time and …

Teva’s New CEO Moves Quickly on Dealmaking

Recently, pharmaceutical company Teva has been facing numerous challenges. These include expiring patents for their top drugs, strong labour opposition to plans for restructuring, conflict between the Board of Directors and Management which resulted in the CEO’s departure, and shareholder unrest. Eyal Desheh, the CFO, has said that they have to make smart deals and partnerships like how Teva has …

Download Presentation: The Advantages of Repositioned Drugs

With healthcare budgets facing increased scrutiny, a cost effective approach to reducing the burden of disease and increasing the productivity of the pharmaceutical industry may be new uses for existing drugs, so called drug repositioning. On the face of it, there are numerous advantages of adopting or integrating a drug repositioning strategy:   Repositioned compounds have the potential to show …

What challenges are principal investigators facing in rare disease research?

Principal investigators and scientists from industry, academia and government have been facing challenges that are not only scientific but also managerial and administrative. These include such responsibilities as garnering financial support, supervising lab staff, mentoring graduate and postgraduate students, teaching, writing papers, serving on committees. Networking with other PIs and senior level executives who have managed to share their time …

The reasons why the whole industry is repurposing drugs

Finding new therapeutic uses for old drugs is a growing trend in the industry. as pharma struggles to discover new blockbuster drugs and see in the practice a way to rebuild their pipelines. Although drug repositioning may sound a strategy only applicable for big pharmaceutical, but small spin-out biotechs are taking advantage of the declining cost of screening of small …

Whitepaper: Drug repurposing through nonhypothesis driven phenotypic screening

Christopher Lipinski, Scientific Advisor, Melior Discovery, Inc. kindly provided this whitepaper on ‘Drug repurposing through nonhypothesis driven phenotypic screening.’ The paper discuss how the pharmaceutical industry must radically evolve its drug discovery tactics from the current unsustainable hypothesisdirected model. Download the whitepaper here for more information > The paper propose here that the most efficient, cost-effective and comprehensive way to …

Is drug repositioning surpassing new brands discovery and development?

Is industry giving more emphasis to recycling and repositioning its compounds instead of discovering and developing truly novel new drugs? Since US FDA added the 505(b)(2) pathway for drug approval 18 years ago, the number of approvals through this amendment has consistently increased, until 2006 when it surpassed the approvals by de novo NDA pathway, designated for proprietary drugs. Many …

Download: ‘Drug repositioning for Alzheimer’s disease: The search for a cure’

Farid Khan, Chief Executive Officer, PharmaKure kindly provided this whitepaper on ‘Drug repositioning for Alzheimer’s disease: The search for a cure.’ The paper suggests that ‘drug repositioning offers great promise for quickly bringing new therapeutic options to patient care’. Download the whitepaper here for more information > Following further research, the paper finds that ‘Existing drugs have been shown to …

Evaluating the Discovering New Therapeutic Uses for Existing Molecules program

In putting the agenda and speakers together for the World Drug Repositioning Congress USA, I came up with a lot of opposing views on the NIH's pilot program on the subject. Of course that for a pilot program, there are no expectations that the project will be flawless, in the meantime it should be targeted to really encourage and set …

Survey on Discovering New Therapeutic Uses for Existing Molecules

Working in conjunction with NCATS, we want to understand the life sciences community’s opinion about the recently launched drug repositioning pilot program – Discovering New Therapeutic Uses for Existing Molecules – spearheaded by NIH’s translational sciences department. Compete the survey now – it will only take a few minute of your time! This brief survey will be used to help …